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GLOSSARY 
CMV    - cytomegalovirus                                              
UTI   - urinary tract infection                                   
EBV       - Ebstein barr virus 
HBV             - Hepatitis B virus 
HCV              - hepatitis C virus 
HIV               - human immunodeficiency virus 
HHV            - Human herpes virus 
HPV              - Human papilloma virus 
PTLD            - Post transplant lymphoproliferative disorder 
HSV          - Herpes simplex virus 
BKVN          - BK virus associated nephropathy 
BAL             - Bronchoalveolar lavage 
PCR                - Polymerase chain reaction 
TAC           - tacrolimus 
MMF        - Mycophenolate mofetil 
PDN             - Prednisolone 
AZA               - azathioprine 
CYC             - cyclosporine 
CNI              - calcineurin inhibitor 
GDF             - graft dysfunction 
DGF              - delayed graft function 
ATN             -  acute tubular necrosis 
NODAT       -  New onset of diabetes mellitus 
ART             - Antirejection therapy 
IFN             - Interferon 
no.               - Number 
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INTRODUCTION 
Renal transplantation has become the most effective means of rehabilitating patients 
with end stage renal disease. In well established centres , 90% 1 year graft survival and 95% 
patient survival is achieved. Inspite of this, infection occurs more than 60% of renal 
transplant recipients and being the one of the main cause of death in renal transplant 
recipients.  
The factors  give a challenge to the clinician for preventing the infection are:1 
(a)  Combination of lifelong immunosuppressive therapy 
(b)  Potential source of infection –endogenous and environmental and allograft itself  
Risk of infections in transplant recipients2 
(a) The occurrence of technical / anatomical mishaps that result in devitalized 
tissue, fluid collections , prolonged keeping of drains, catheter, endotracheal 
tubes, vascular access devices which compromise the barrier. 
(b)  The epidemiological exposure of the patient encounters divided into those occur 
in the community and another is those occurring in the hospital and donor 
derived and recipient derived exposures. 
(c) individuals net state of immunosuppression 
The interaction between the net state of immunosuppression and the environmental 
exposure should be a semiquantitative one. If  the net state of  immunosuppression is 
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minimal then an overwhelming exposure only cause the disease . Conversely if the net state 
of immunosuppression is high , the even minimal exposure will cause the disease. 
Renal transplant recipients are susceptible to infections by different organisms. 
Impaired inflammatory responses due to immunosuppressive therapies hide the clinical and 
radiological findings affected by microbial infection. As a result ,evaluation and diagnosis is 
delayed. Specific microbiologic diagnosis is essential both for optimization of antimicrobial 
therapy and to avoid unnecessary drug toxicities. Routine antimicrobiologic prophylaxis is 
aimed at common infection i.e  that includes trimethoprim-sulphamethoxazole 
(toxoplasmosis , pneumocystis, Nocardia, UTI) and valganciclovir( CMV and herpes groups) 
and antifungal (Kidney-pancreas transplantation) 
In this study  , we have   been made to analyse the risk facors and clinical profile  and 
outcome of viral infection in renal transplant recipient. 
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AIMS AND OBJECTIVES 
 
1. To study  the clinical profile of  viral infections in  renal transplant recipients. 
2. To study the  risk factors for viral infections and the  effect of viral infections on graft 
outcome. 
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REVIEW OF LITERATURE 
 
Immunosuppression make the recipient susceptible to many viral pathogens either 
due to community exposure (adeno,influenza) or commonly transmitted with allograft 
(CMV, EBV) or as a result of more distant exposure due to more immunosuppression ( 
Chickenpox and varicella zoster)3. Mutilple simultaneous infections either two viral or viral 
and nonviral infections are also common. 
Effects of viral infection: 
It is divided into effects of invasive viral infection or form effects mediated by 
inflammatory responses or by alteration of host immune and inflammatory response. Direct 
effects due to tissue invasion and indirect effects due to release of cytokines causing 
immunomodulation4  and further immunosuppression and producing more infections and also 
alter the expression of surface antigens provoking graft rejection.  Infection with one virus 
stimulate the replication of other virus. Viral replication can also lead to production of cross 
reactive T cells directed  against shared antigen between virus and the graft. . 
The specific terms latency and reactivation is important in any transplant recipients. 
Many viral infections after transplantation  result from  the reactivation of latent viral 
infection in the host or from allograft. Latency and reactivation is noted in herpes group of 
viruses. Viral latency is characterized by due to low level or absence of detectable viral 
antigens and minimal transcription of productive  or lytic cycle genes  and expression of 
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latency associated viral transcripts5. Viral latency interrupted periodically, leads to 
reactivation of infectious virus. 
CMV is latently present in CD14 monocytes and CD34 progenitor cells. EBV is 
latently present in lymphocytes. 
Risk factors  of viral infection after transplantation: 
The risk is depend upon the variety of factors such as the intensity , virulence and the 
immunosuppressive regimen and the presence of preexisting antiviral immunity and the viral 
exposure mechanism. Steroids (reactivate HBV and HCV  ) and induction of T cell depleting 
antibodies ( activate Herpes and HIV) ,  Tacrolimus (BK  Virus),ATG (CMV), MMF( late 
CMV, Herpes zoster) and costimulatory blockade alters the susceptibility to viral infection  . 
Time pattern of viral infection: 
Patients with history of herpes simplex infection present within 1 or 2 months after 
transplantation. Infections acquired from the donor such as HBV , HCV or HIV appear in the 
in the first month of transplantation. Earlier onset of hemophagocytic syndrome6  due to 
EBV, CMV, VZV, HIV,  HHV8, Parvovirus ,measles  occur just after the transplantation. 
CMV both reactivation and  new disease acquired in the peritransplant period appear in 
months 1to 4 or after cessation of prophylaxis .CMV retinitis and colitis occur later (6 to 12 
months or later). BK virus nephropathy half occur in the first six  month  after transplantation 
and other half in the later period. Influenza and adeno  and RSV  and entero  and para 
influenza can appear at any time. HHV6 and 7 can appear in  the earlier months and HHV 8 
occur in the later time period.  
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EBV infection and PTLD  can occur within one year.  In Hepatitis B and Hepatitis C 
infection, previously positive reactivation  occur in earlier months and acquisition of new 
infection reactivation occur in later months. Individual risk factors must be considered for 
evaluation of skin and anogenital lesion caused by papilloma virus. Herpes simplex virus 
infection reactivate at the earlier months of transplantation. 
 CYTOMEGALOVIRUS INFECTION: 
CMV is the the significant cause of morbidity and mortality among transplant 
recipients. Human CMV or human Herpes virus 5 is the largest known human virus. It is 
double stranded DNA virus and icosahedral in shape and consists of inner core and a capsid 
and an envelope. White blood cells, CD13+ve cells are in particular are the reservoir of  
CMV. 
CMV  replication produces the immediate early, early, and late antigens. The early 
antigen gene products direct viral DNA synthesis. The three common drugs used in CMV 
infection act by interrupting the DNA synthesis. Late antigens appear after DNA synthesis 
and monitoring the late antigen level may be more relevant when assessing the response to 
therapy. 
CMV has the capability to alter  the expression of MHC class I molecules which may 
allow the evasion of recognition by cytotoxic T cells , but make infected T cells vulnerable to 
NK cell attack and directed the production of viral IL- 10 blocks proinflammatory cytokine 
synthesis and suppress  the ability of macrophages  to serve as antigen presenting cells.  
After the primary infection, the virus establishes the latency within host. TNF alpha 
(induced by allogenic response after transplantation, anti thymocyte globulin  and sepsis 
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induce ie gene expression through activation of major ie promoter enhancer which reactivates 
latent CMV7. 
Risk factor and pathogenesis: 
CMV infection occurs within  1-4months  of transplantation. Symptomatic CMV 
infection occurs in 20-60% of  all transplant recipients.  In CMC vellore, seropositivity in our 
population is about 98%. The prevalence of clinical CMV disease in  post transplant 
30%consistent with reinfection and reactivation. 
The Major risk factors  responsible are the nature  and dose of immunosuppressive 
medication, MMF >3g/day. Sirolimus seems to have a protective role.  Induction with 
depleting agent directly activate viral infection.  Recipient / Donor serology status, 
immunosuppressive medication, HLA mismatch, depleting induction agents and anti 
rejection therapy ,neutropenia, co infection with HHV6 and HHV7  and older donor. Use of 
anti lymphocyte antibody is associated with 2-5 fold increase in the rate of CMV disease. 
Clinical Manifestation: 
(1) CMV infection : evidence of CMV replication  
(2) CMV disease :  evidence of CMV infection with attributable symptoms. 
CMV disease is  further divided into viral syndrome and tissue invasive disease 
Late onset of CMV- detection of CMV DNAemia > 100 days after transplantation . 
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Effects of CMV infection: 
Direct effects of CMV   Indirect effects9 of CMV 
Fever and neutropenia syndrome risk of opportunistic infection 
Pneumonia risk of graft rejection 
Myelosuppression increase the risk Of PTLD 
Gastrointestinal – colitis , ulcers , perforation        increase the risk of HHV6 ,7 infection8 
Hepatititis    arteriosclerosis / vasculopathy 
Pancreatitis   accelerate the atherosclerosis 
Chorioretinitis   increase  the risk for NODAT 
 
Diagnosis: 
 Serology- not useful 
 CMV pp65 ag- utilizes the polymorphonuclear cells in peripheral blood. It should 
be processed within 6-8hours. Easy to perform but immunostaining skills 
required. 
 PCR-detects CMV DNA in whole blood , WBC, plasma and serum.PCR is highly 
suitable for BAL , CSF and biopsy specimen. 
 Hybrid capture assay: rapid detection of viral DNA , less sensitive than PCR 
 Branched DNA: less sensitive , reproducible 
 NASBA: detects viral RNA  and highly sensitive 
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 Tissue invasive disease has to be proved using culture of tissue involved , 
histopathology testing with immunostaining, immunohistochemistry  or in situ 
hybridization 
Prevention: 
Two  main strategies  - (1)  Universal prophylaxis 
                                (2)  Pre-emptive therapy 
 In universal prophylaxis, valganciclovir  900mg/day (now 400mg/day is enough) are 
all or subset of recipients at risk for 3 months. Valganciclovir is advantageous due to lower 
pill burden and increased compliance10. 
 In preemptive therapy(highly suitable for low risk (D-/R-) surveillance for viral 
replication is done with pp65 assay or CMV DNA PCR periodically. When threshold 
genome copies are exceeded, antiviral therapy is started with IV ganciclovir 5mg/kg or oral 
valganciclovir 900mg and weekly monitoring of copies continued until CMV is no longer 
detected. 
Treatment:  
 Established clinical proven CMV disease  should be treated with intravenous 
ganciclovir 5mg/kg twice daily, for 3 weeks (to be adjusted for renal dysfunction) 
(>70ml/min-5mg/kg evey 12 hr ,50-69ml/min-2.5mg/kg every 12 hrly, 25-49 2.5mg/kg every 
24hrly,10-24ml/min 1.25mg/kg every 24hrly, <10ml/min- 1.25mg/kg x3/wk after HD) 
Victor trial proved that valganciclovir is non inferior to  IV gancicylovir in solid 
organ transplant recipients with non life threatening disease11. Reduction of 
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immunosuppression  should be done in high viral loads , severe life threatening disease, 
leucopenia . 
Weekly monitoring of viral load is essential. Therapy can be stopped only after viral 
clearance achieved as assessed by PCR or pp65 antigenemia assay. After initial treatment, 
secondary prophylaxis with valgancicylovir 900mg/day ( to be adjusted for renal 
dysfunction). 
 (crcl >60ml/min—900mg/day ,40-59ml/min - 450mg/day, 25-39ml/min-450mg every other 
day, 10-24ml/min -450mgx2/wk , <10ml/min-NR). 
In one study 6.2% of CMV isolates had UL97or UL54 mutations determining 
ganciclovir resistance.  In UL 97 mutation only, if low level mutation    high dose Iv 
ganciclovir to be given  If no response switch to foscarnet. If UL 54 mutation ( normally 
associated with UL 97 mutation)  If  GCV-CDV mutation consider foscarnet and adding 
CMV immunoglobulin. If Ul54polFOS-GCV mutation cidofovir or and half dose foscarnet 
and  GCV12 to be considered. 
BK VIRUS INFECTION: 
 BK virus has been classified in the polyoma viridae family. Viruses  in the group 
include JC virus , simian virus  and monkey polyoma virus besides BKV. 
The polyoma virus are a family of small, nonenveloped DNA viruses with 
icosahedral, capsids 40-44nm in diameter. The genome comprise of  
(a) Non coding control region 
(b) Early coding region coding for small and large T antigen 
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(c) Late coding region for viral capsid proteins and agnoprotein13 
The virus attaches to the host cell plasma  membrane through binding of viral capsid 
protein  VP-1. The entry into the cells is through a caveola mediated endocytosis. After entry, 
virus migrates through cytoplasm, microtubules and nuclear pores into the host nucleus. 
Ultimately cells are lysed and mature virions are released.14 
Mode of transmission: 
Predominant mode of transmission is the donor allograft as the virus stays latent in 
the kidney15.  BKV DNA has been amplified in 0-40% urine samples and 1% nasopharyngeal 
aspirates of infants with respiratory infection. Feco-oral transmission is also possible . 
Clinical features: 
Primary infection is common in 80%. Usual manifestation is respiratory illness and 
occasionally cystitis has been reported. Then virus enters a latent infection and reactivation 
happens with the development of immunosuppressive states. The reactivation leads to BK 
virus nephropathy and manifests with renal dysfunction.  Progressive renal failure occurs in 
30-60% of cases16. Occasionally subjects can also present with ureteric obstruction, 
hydronephrosis and cystitis have been reported.  
Risk factors for BKVN: 
Donor related   : deceased donor, active BKV or CMV infection, donor 
seropositivity                    
Recipient related : old age , male , Caucasian race, DM, CMV infection, ATN, 
absence HLAC7 
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Transplant related :  cold ischemia time, DGF, MMF, tacrolimus, Anti rejection 
therapy, drug toxicity , ureteral stent placement 
Viral related        :  variant in VP 1, sequence alteration in NCCR 
Laboratory  Diagnosis: 
 Diagnosis of  BKV infection is based on documentation of viral cytopathic effects 
(urine decoy cells), the virus itself  in blood and  urine (Haufman body)  and renal 
histological finding of BK virus nephropathy and serum IgG /IgMantibodies 
 Demonstration of BKV inclusion in tubular epithelial or Bowmans capsular 
epithelial cell  
 Plasma BKV DNA>7000copies/ml 
 Urine decoy cells>10/cytospin 
 Urine BKV >1x107 copies/ml 17 
 Urine BKVmRNA Rt-PCR >6.54X105copies/ml18     are useful to diagnose 
BKVN                    
Pathology: 
BKV initially affects focally, and is missed in 25% to 37% of samples. Intranuclear 
viral inclusion bodies in epithelial cells , tubular cell injury and lysis define BKVN. Infected 
tubules show many cytopathic changes including anisonucleosis of nuclei with 
hyperchromatasia and smudging and clumping and peripheral margination of chromatin. The 
nuclei are enlarged and most characteristic is the presence of basophilic intranuclear 
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inclusion with no halo19. Immunostaining of tissue the presence of SV 40  large T antigen is 
useful for diagnosing BKVN. 
Different pathogenesis:  
In Acute BKV reactivation  low grade inflammation  leads onto cytotoxic 
lymphocyte control  BKV replication  so reduction  
of immunosuppression required20 
In chronic BKV replication   massive inflammation  cytotoxic lymphocytes 
migrate into  Inflammatory area and attack/damage 
graft cells  reduction of immunosuppression is 
harmful. Immunomodulation is necessary. 
Treatment: 
 Reduction of immunosuppression 
 Modification of immunosuppression :TacCyA or Tac  siro, MMF  leflunomide 
 Discontinuation: of Tac or CyA or MMF –continue with double therapy 
Two drugs has shown to be effective—cidofovir and leflunomide 
Fluroquinolone antibiotics have also shown to improve graft function22 
HEPATITIS C VIRUS: 
 Hepatitis C virus is a flaviviridae family. Six  HCV genotypes with several distinct 
subtypes has been identified. As virus replicates over time, selective pressures from the 
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immune system or antiviral treatment or both cause viral population to evolve. This mutant 
version of genotype is called as quasispecies.  
Impact of pretransplant Hepatitis C on post transplant outcome: 
 Orloff and collegues23 reported the liver biopsy findings at 3 to 7 year after kidney 
transplantation in HCV positive subjects are 12% have chronic active hepatitis, 50% have 
mild hepatitis  and 38% had normal histology. HCV has no adverse effect on graft survival. 
Lee and coworkers24  told that HCV infection did not reduce renal allograft or patient 
survival. But if more liver disease,  greater prevalence of sepsis in the HCV infected 
recipients. 
Periera and coworkers25 computed that the recipients who  are HCV positive before 
transplantation, relative risk of post transplantation liver disease was 5,  graft loss was 1.3 
and death was 3.3 
NODAT and Hepatitis C:  
NODAT develops within 36 months of kidney transplantation in upto 24% of 
patients26. HCV infection is  associated with increased insulin resistance. There was  eight 
times increase in NODAT in patients treated  with tacrolimus (58%) compared with 
cyclosporine (7.7%)27 
HCV associated Post transplantation glomerulopathy: 
Chronic HCV infection has been associated with the development of mixed essential 
cryoglobulinemia28. Nearly half of HCV infected patients who have type 2 or 3 
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cryoglobulinemia develop renal complication, including MPGN and membranous 
nephropathy. 
Disease progression:  
HCV viral loads increase approximately 1.0 to 1.5 log 10IU/ml after  transplantation. 
Treatment : 
Treatment of HCV in transplant recipients are not recommended because of risk of 
precipitating acute rejection. There are clinical circumstances in which risk – benefit 
assessment to be done. HCV associated glomerulonephritides can recur after kidney 
transplantation and cause progressive renal dysfunction and antiviral therapy is needed to 
prevent the graft loss. Severe cholestatic hepatitis and cryoglobulinemic vasculitis need IFN 
therapy.  
Acute rejection has been reported in several published studies with rates varying from 
15 to 64% who were treated with interferon. IFN with ribavirin combination therapy is better 
if the patient has no graft dysfunction. In renal transplant recipients, ribavirin tolerance 
varies. Associated hemolytic anemia require high amount of rhEPO or ribavirin dosage 
modification. 
HEPATITIS B INFECTION:  
A recent systematic review and metaanalysis  estimated that 3.07% of  non tribal and 
11.85%of  tribal population . HBV is hepatotropic virus enveloped , partially double stranded 
DNA virus that is a member of hepadna virus family. The genome of HBV encoded 4 
different genes. The C gene encodes the hepatitis core antibody and the P gene encodes the 
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hepatitis B polymerase, the S gene encodes 3 different polypeptides of surface antigen or 
protein and the X gene encodes proteins potentially involved in transactivation of viral 
replication. 
HBV after renal transplantation: 
Fabrizi and collegeues30 shows that Hbs Ag seropositivity was an independent risk 
factor for death after renal transplantation with a relative risk of 2.49. Immunosuppression  
may stimulate HBV replication by a variety of mechanism for instance by diminishing 
activity of cytotoxic T lymphocytes. In addition a glucocorticoid responsive element that 
enhances the replication31 and Azathioprine and CNI also enhance replication . 
Krishnamoorthy et al32 4.5% post transplant seroconversion among those previously negative 
and 20% among those who are anti HBc positive.  
Two different stratagies to prevent HBV are prophylactic and preemptive treatment 
stratagies. Prophylaxis is given only to those who have detect a DNA or HBs ag or all HBV 
infected patients. In the preemptive strategy, a new appearance of HBV DNA or 10 fold rise 
in HBV DNA level result in requiring treatment. Lamivudine dramatically improved the 10 
year survival rate from 55% to 90%. IFN is not used ,it can cause steroid resistant rejection , 
tubulointerstitial nephritis and direct nephrotoxicity. Since lamivudine is prone to develop 
resistance, entecavir is used .Telbivudine and tenofovir have not been studied in renal 
transplantation. Combination therapy with multiple anti viral agents may be necessary if 
resistance develops. 
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HERPES GROUP OF VIRUSES: 
VARICELLA ZOSTER VIRUS: 
 Human herpes virus belongs to alpha herpes virinae. It produces 2 types of disease 
1. 90% of patients –herpes zoster 
2. 10% of patients –at risk of primary infection 
 Incidence 4-12%33 
Produces  a localized dermatomal zoster or multidermatomal or disseminated Zoster 
with or without visceral involvement. Median time of onset- 9 month34. 
Complication 
 DIC and hepatitis and pneumonitis and in primary infection pancreatitis and orchitis  
and rarely infection of allograft and encephalitis are documented. 
Diagnosis : 
Culture of varicella zoster in cell lines , Tzanck smear.  
Pre transplant screening for previous VZV infection should be performed and naïve 
patients should be vaccinated. But it is a live vaccine,  transplant should not be proceeded 
within 4 to 6 weeks. A VZV naïve transplant patient who is exposed to someone infected 
with  varicella  should receive varicella immune globulin within 96 hours of exposure. 
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HERPES SIMPLEX VIRUS INFECTION: 
Human herpes virus 1- HSV – sub family  alpha herpes virinae.  Prevalence-53% 
Herpes simplex most commonly cause reactivation infection . Following primary infection 
the virus stayed in the sensory ganglia. In the absence of prophylaxis , HSV seen in the first 
month after transplantation. 
Reactivation  or Primary HSV infection results in oral or mucocutaneous lesion , 
hepatitis35 and pneumonitis, tracheobronchitis, esophagitis. Disease may be severe and 
prolonged in viral infection. 
HSV is the most common cause of encephalitis in transplant recipients. Esophageal 
ulcer produced by HSV can mimick candida.  Mutivisceral infection is fatal. 
Diagnosis: 
Direct fluorescence  antibody from vesicular lesion, HSV PCR in CSF or  visceral 
tissue sample. 
Treatment: 
Effectively treated with acyclovir.  Acyclovir resistance may arise from mutation in 
the genes for thymidine  kinase or DNA polymerase. Foscarnet, cidofovir, topical trifluridine  
considered for resistant strains36. 
HUMAN HERPES VIRUS 6, 7 : 
It belong to subfamily of betaherpes virinae, genus Roseola virus. Both viruses  are 
highly prevalent in adults. After the primary infection, these viruses enter into a latency   and 
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that remains in the host for life long time. Both viruses are lymphotropic. Most infection in 
renal transplant recipients are due to HHV 6. 
 HHV6 useCD46 molecule as a receptor- infects lymphocytes , monocytes, 
epithelial, endothelial cells. 
 HHV7-use CD 4molecule as a receptor- infects only lymphocytes. 
HHV 6 - produce fever, rash, encephalitis, hepatitis, myelosuppression, interstitial 
pneumonitis 
Both viruses 
(a) have immunomodulating properties.37- have the ability to change the   expression 
of immune activation molecule, modulate the expression of cytokines and induce 
apoptosis.     
(b) HHV 7 act as a cofactor for HHV6 and CMV reactivation 
(c) HHV6 and HHV7 act as a cofactor for CMV disease and acute rejection. 
Diagnosis: 
Quantitative and qualitative molecular assay, tissue immunohistochemistry, 
peripheral blood mononuclear cell culture. 
Treatment: 
Reduction of immunosuppression and ganciclovir, foscarnet and cidofovir tried. 
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HHV 8: 
Belongs to subfamily of gamma herpes virinae. 
 It is associated with Kaposi sarcoma, primary effusive lymphoma, muticentric 
castleman’s disease.  Transplant associated Kaposi sarcoma 0.2 to 5% of renal transplant 
recipients. Of all the tumous, Kaposi sarcoma occurs at the shortest interval. It is due to 
upregulation of VEGF in vascular endothelial cells.38 
Treatment: 
Reduction of immunosuppression, chemotherapy , change into sirolimus. 
EBSTEINBARR VIRUS: 
Belong to Gamma herpesvirinae, genus-lymphcryptvirus. 
In transplant recipients, primary EBV infection produces a mononucleosis type 
syndrome with or without lymphadenopathy or pharyngitis. Meningitis ,  hepatitis and 
pancreatitis are noted. EBV infection remits and relapses in children.This syndrome suggest 
relative overimmunosuppression 
EBV plays a role in the development of PTLD39. EBV increase the risk 10 to 76fold. 
Post transplant Nonhodgkins lymphoma is common complication. PTLD in transplant 
recipients has increased extranodal involvement, poor response to conventional therapy and 
poor outcome. Most of the disease, the origin is B cell . PTLD occuring  late >1to 2 years 
after transplantation are EBV negative. 
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Clinical presentation: 
 Fever, mononucleosis like syndrome, 
 Gastrointestinal bleeding , obstruction or perforation  
 Abdominal mass lesions infiltrative disease of allograft 
 Hepatocellular or pancreatic dysfunction 
 CNS disease 
Diagnosis: 
 Quantitative EBV viral load testing- serial assay are useful40 
 Use whole blood sample rather than plasma sample 
Management: 
 Reduction of immunosuppression 
 Combination of anti B cell therapy(rituximab) 
 CHOP regimen41 
 Adoptive immunotherapy with stimulated T cells 
PARVOVIRUS B19: 
 It is a small , non enveloped single stranded DNA virus-parvoviridae family-
erythrovirus genus. 
B19 genome encodes 2 structural capsid  proteins  VP1, VP2. 
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Pathogenesis: 
 B19 virus targets the erythroid progenitors in the bone marrow by binding to 
glycosphingolipid globoside also known as blood group antigen P antigen42 is expressed in 
more in erythroblasts  The existence of cellular coreceptor integrin is necessary for 
successful infection. Integin is expressed in erythroid progenitors . Ku80 also act as a 
possible coreceptor43. 
After B19 infection of erythroid progenitors , cell death ensues either by cell lysis or 
by apoptosis mediated by NS1 protein. 
Clinical manifestation: 
Anemia is the predominant clinical manifestation. In normal hosts, at approximately 8 
days after infection parvovirus induces the lysis of RBCS and prolonged for about 10 days. 
But in  immunocompromised state it produces a chronic anemia. Onset of anemia has been 
reported  from 2 week to 63 month after transplantation. 
Renal manifestation- proliferative glomerulonephritis, collapsing glomerulopathy44, 
thrombotic microangiopathy and acute allograft rejection and renal transplant dysfunction 
Liver dysfunction, fibrosing cholestatic hepatitis , encephalitis and cerebral vasculitis. 
Diagnosis: 
Parvo virus DNA by PCR  
Bone marrow- pure red cell aplasia- reduction of erythroid  cell lineage and giant 
erythroblasts. 
 
 23 
Treatment:  
 Commercial  IV Ig useful 
 Reduction of immunosuppression 
 spontaneous remission in some patients. 
 Switch from Tacro to cyclosporine45. 
ADENOVIRUS: 
It is a nonenveloped , double stranded DNA viruses  
Has 51 immunological distinct types which are further classified into 1to6(A-F) 
subgroups on the basis of hemagglutinin properties , DNA homology , oncogenic potential 
and clinical disease. Incubation period is from2 days to 2 weeks. It is a rare pathogen in 
kidney transplant recipients. The most common manifestation is hemorrhagic cystitis46. Other 
manifestion is pneumonitis  and pyelonephritis , necrotizing tubulointerstitial nephritis and 
gastroenteritis and necrotizing hepatitis 
Diagnosis: 
 Adenovirus DNA PCR in the blood and  urine 
Treatment:  
 Reduction of immunosuppresion 
 IVIg  
 Cidofovir and ribavirin 
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HUMAN PAPILLOMA VIRUS INFECTION: 
HPV are small DNA viruses and it infects epithelial tissues of skin and mucous 
membranes. Among 100 distinct subtypes, 15 subtypes have been designated with invasive 
cervical cancer.  
Clinical manifestation: 
It is the important cause of more than 90% of cervical and anal cancers and a large 
proportion of vaginal and penile cancers and also head and neck cancer. HPV – 16 accounts 
for 50% cervical cancer.  Most common clinical manifestation is anogenital and cutaneous 
warts and condyloma. HPV 6 and 11 produce genital warts and also respiratory 
papillomatosis. HPV 1 produce palmar and plantar warts. 
Diagnosis: 
 Elisa for IgM and IgG for HPV  
 HPV DNA PCR 
 Histology  
Treatment : 
 Topical salicylic acid/lactic acid or imiquimod cream 5% 3 times per weekfor 16 
weeks47 
 Cryotherapy q1-2 weeks of liquid nitrogen spray 
 If not responded-surgical removal. 
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HIV INFECTION: 
 HIV virus belong to retroviridae, genus lentivirus  
 HIV is not a contraindication for renal transplantation 
 Pts CD4 count >200cells/cumm for atleast 6 months and undetectable HIV viremia 
<50copies/ml and demonstrable adherence and a stable HARRT  regimen for >6 months and 
absence of AIDS defining illness is the inclusion criteria for renal transplantation.48 
 Main challenges in the clinical management of renal transplant recipient are 
pharmacological interaction between immunosuppressive drugs and HAART therapy and 
higher rate of acute rejection (upto 25% ) 
RESPIRATORY VIRUSES: 
Various viruses  can cause respirapry disease in renal transplant recipient including 
adeno, parainleunza, influenza, RSV, rhino, corona virus. These viruses can lead to upper 
respiratory tract disease as well as bronchitis , pneumonitis and pneumonia 
Treatment: 
 Supportive care influenza  
 Treated with ostelmivir or zanamavir 
 Amantadine is not recommended because it treats only influenza and produces the 
resistance 
 Ribavirin for Respiratory syncytial virus 
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MATERIALS AND METHODS 
 
Study Place           : Department of Nephrology 
Study  Design        : Cross-sectional  descriptive prospective and retrospective study 
Period of study     : Two years 
Study population   : Patients attending the  Transplant clinic, Nephrology Department 
in Rajiv Gandhi Government General Hospital. 
Ethical approval  : Obtained from ethical committee headed by Dean, Madras 
Medical  College. 
Consent                 : Obtained from all patients 
Inclusion criteria: 
       Renal transplant recipients  diagnosed  with  viral  infections  diagnosed by either    
clinical   or laboratory evidence or serological methods or radiological or by renal biopsy 
Exclusion criteria: 
 Renal transplant recipients with  empirical  antiviral therapy given. 
This study was done in prospective  and retrospective manner. Retrospective cases 
selected  by examining the case records and examining the patients while coming for follow 
up and in prospective cases are followed during the time period of study.  
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All the selected transplant recipients underwent detailed history and clinical 
examination. Some of the viral infections diagnosed by clinical examination alone  like 
varicella Zoster and cutaneous warts caused by human papilloma virus. 
All the patients undergo routine blood investigations like complete hemogram and 
urine routine  and urine culture and peripheral smear and renal function tests and liver 
function tests   and blood sugar  and  serological tests wherever necessary. All the patients 
were undergone USG KUB and Doppler wherever necessary was done. 
CNI level was done whenever necessary we prefer to take Co level by 
chemiluminescence method  providing that patient not having diarrhea at that time and 
confirming regular compliancy 
Renal biopsy was  done in selected patients whenever necessary like graft dysfunction  
or proteinuria.  Before renal biopsy HBS Ag, anti HCV and HIV antibody by ELISA  and 
coagulation parameters and bleeding time and platelets to be done. In our department, renal 
biopsy is performed under ultrasound guidance with needle biopsy gun. Patient lies in supine 
position. Upper  pole of the kidney is marked . Lower pole of kidney is avoided in contrast to 
native kidney biopsy. After infiltration with 2% lignocaine, stab incision is made using a 11G 
blade. While asking the patient to hold breath, 16G biopsy needle gun is fired to get the 
sample. Patient is then asked to lie flat for 12 hours, with strict monitoring of pulse, blood 
pressure and urine output. Biopsy sample was sent in formalin & Michel’s fixative   for light 
microscopy (LM) and Immunoflourescence (IF) respectively. All the biopsy samples were 
reported by single nephropathologist to avoid bias. 
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For LM, all samples were stained with hematoxylin and eosin (H&E), periodic acid -
Schiff (PAS), Masson trichrome and Jones silver methenamine. For IF,3 µ sections were 
stained with florescent tagged antibodies to IgG, IgM, IgA, C3, C1q, fibrinogen, Kappa and 
lambda chains, c4d. For suspecting BK virus   immunohistochemistry using SV 40 staining 
was done  and suspected EBV immunhistochemistry was done. 
Radiological investigation X ray chest and USG  abdomen and CT chest was done 
whenever necessary and PET scan was done whenever necessary. 
If presented with pulmonary involvement  bronchoalveolar lavage was done and BAL 
fluid sent for cytology and culture analysis. 
If presented with CNS  involvement , CSF fluid sent for quantitative  PCR. 
 If presented with Gastrointestinal tract involvement, mucosal biopsy and upper GI 
endoscopy and colonoscopy was done. 
If presented with cutaneous involvement or mucocutaneous involvement , scraping  
and examine  Tzanck  smear preparation  was done. 
Those patients with fever, leucopenia and graft dysfunction suspected to 
cytomegalovirus infection, CMV pp65 antigen  is tested . Blood was sent through   EDTA 
anticoagulated tube and analysed within 6-8 hrs It is measured in the form of >10/2X105 
neutophils. If the total WBC count was less than 1500 either we will repeat pp65 antigen or 
CMV DNA PCR because it may be false negative. After finishing of treatment , we are again 
monitoring for viral clearance. Sometimes renal allograft biopsy shows viral inclusion body. 
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For suspecting BK virus either doing immunohistochemical staining with SV40 or by 
quantitative DNA PCR in the blood. We are not doing urine BK DNA PCR due to logistic 
reasons. Renal biopsy shows viral inclusion body in the tubular epithelial cells. 
In patients with acute hepatic dysfunction hepatitis A and E virus antibody and 
chronic dysfunction Hepatitis B and C virus  was done. If it was positive quantitative PCR 
was done and portal Doppler and Usg abdomen was done. Liver biopsy was done before 
starting treatment in Hepatitis c  and hepatitis B. We are not doing liver biopsy in regular 
basis before starting of treatment. We are regularly monitoring of viral load by  every 3rd 
monthly or 6th monthly.  If patient develops cirrhosis of liver then doing ascitic fluid analysis 
was done. 
If the patient develops anemia suspecting to be parvovirus  quantitative DNA PCR 
was done and bone marrow aspiration  was done  to confirm the erythroid cell lineage 
affection and reticulocyte count was monitored. 
In suspecting Herpes simplex virus infection, in encephalitis CSF quantitative PCR 
was done and in  cutaneous involvement, Tzanck smear examination was done. 
For suspecting EBV , PET scan was done  to find the increased FDG uptake and 
immunohistochemical staining of renal biopsy or lymphnode biopsy  and antibody to EBV 
screening and quantitative PCR was done. 
For those patients having gross hematuria, suspected to be adenovirus, quantitative 
PCR adenovirus  to be done. 
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If the patient present with rash with leucopenia CMV serology was negative, then 
suspect HHV6 or HHV7 infection and  then quantitative PCR to be done.     
If the patient found to be HIV serology was positive, then CD4count  and then 
followed up regularly and monitor  for drug interaction. 
Statistical analysis: 
Baseline characteristics of all patients were presented descriptively with mean ± SD 
for continuous variables and percentage for categorical variables. We used Mann-Whitney 
test for univariate comparison of continuous variables and Fisher exact t test for categorical 
variables. Multivariate analysis was done by binary logistic regression analysis. p value of 
less than 0.05 was considered as statistically significant. It was performed using medcalc 
software. 
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RESULTS AND OBSERVATION 
 There were 356 patients were analysed  in a prospective and retrospective manner. 
Mean age of recipient  - 29.8 years  
Mean age of donor   -  41.7 years.  
Male: female  - 3.7:1 
Live: cadaver               - 4.08:1 
 Immunosuppressive regimens: 
CSA/AZA/PDN - 33 (65.4%) 
CYCLO/MMF/PDN - 46 (12.9%) 
TACRO/MMF/PDN - 75 (21.0%) 
TACRO/AZA/PDN - 2(0.5%) 
Induction therapy was given—8 patients. 
ATG   -  3 patients 
IL2 receptor antagonists- 5 patient 
 
Total infective episodes  - 741. 
VIRAL INFECTION: 
Total no. of viral infective episodes -  224 
Total no. of persons affected by viral infection - 152. 
42.6% of patients affected by viral infection. 
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On an average 72 persons have more than one viral infective episode. 
Male: female - 3.47:1 
Live : cadaver: 5.04:1 
Onset of viral infections: 
Phase  I  ( <1 month) - 9 episodes(4%) 
Phase II (1-6 month)  - 74 episodes (33%) 
Phase III (>6 month) - 119 episodes (53.1%). 
Pre transplant hepatitis C positive - 20 
Pretransplant hepatitis B positive - 2 
Risk factors: 
NODAT  : 53persons (34.8%)  
ART  :  55 persons (36.1%) 
CNI toxicity  : 44 persons (28.9%) 
Risk Factors With viral infection 
Without viral 
infection p value 
NODAT 53 27 <0.001 
Anti rejection therapy 55 45 <0.004 
CNI toxicity 44 76 0.113 
 
NODAT  and ART is the significant risk factor for the development of viral infection. 
  
 33 
Outcome : 
GDF   -51  (33.5%) 
Graft  loss - 15 (9%) 
Death -18 (11.8%) 
Outcome GDF Graft  loss death 
With viral infection 51 15 18 
Without viral infection 71 55 78 
p value <0.001 <0.001 <0.001 
 
Viral infection is one of the  most contributing factor for the persistent graft 
dysfunction and graft loss and death of the patient. 
Cytomegalovirus infection: 
Total persons affected by CMV-62 
Male : female : 46:16 
Live : cadaver - 54:8 
Prevalence of CMV infection—17.4% 
Mean time of onset –4+1month after transplantation. 
 Phase1 (<1 month)-1 
 Phase II (1-6 month)-40(64.5%) 
 Phase III (>6 month)-21(33.8%) 
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Clinical manifestation: 
 CMV syndrome - 37 
 Skin/palatal /oral ulcer- 9 
 Pneumonitis  -  7 
 Encephalitis  -  1 
 Retinitis  -  2 
 Colitis  - 12 
Retinitis present in late CMV infection. 
Leucopenia is present in 72.5% of patients. It is the one of the associative factor in 
active CMV infection. (p value -<0.001) 
Risk factors: 
Risk factors  With CMV Without CMV p value 
NODAT 15 65 0.7387 
Anti rejection therapy 27 83 <0.03 
CNI toxicity 24 100 0.556 
 
Anti rejection therapy is the most contributing factor for development of CMV infection. 
Associated other infections: 
Other 
Infections  
Fungal 
infection TB 
Bacterial 
infn 
Other viral 
infn 
CMV +ve 19 6 18 22 
CMV-ve 26 29 162 130 
p value <0.01 1.07 <0.002 <0.002 
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CMV infection is a risk factor for developing bacterial and other viral infection and 
fungal infection (p Value <0.05) but not for tuberculosis.(P-1.07 – not statistically 
significant) 
Recurrent CMV – documented in 3 patients. 
1 patient developed resistance to gancicyclovir 
Outcome: 
Outcome GDF Death 
CMV+ve 28 14 
CMV-ve 94 82 
p value <0.05 0.434 
 
 Among the viral infections, CMV and BK virus are the commoner viral infections 
producing persistent and progressive graft dysfunction. In CMV infection GDF persistence   
(45.1%) is statistically significant. 
 GDF Death 
Early onset of CMV 13 5 
Late onset of CMV 16 12 
p value <0.032 <0.005 
 
Compared to early onset CMV,  late onset CMV is the more significant contributing 
factor for patient survival. 
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BK VIRUS INFECTION: 
Total no. of patients  -  3 
Male:female - 2:1 
Live:cadaver               - 2:1 
Prevalence - 0.8% 
Mean time  of onset of transplantation-8 month + 4 month after transplantation. 
Comorbidities: 
H/O anti rejection therapy - 1 
Associated herpes Zoster - 1 
Presentation: 
Ureteric stenosis  - 1 
Interstitial nephritis  - 1 
Outcome GDF 
BK virus infection 3 
p value  <0.039 
 
All 3 patients affected by BK virus have persistent graft dysfunction. 
Since logistic reasons BK virus qualitative DNA not done in everybody & only urine 
decoy cells were sent. If it is  positive , we will do DNA PCR.  That is the reason it is less 
prevalence in our study. 
HEPATITIS C VIRUS : 
Total no of patients affected by HCV+VE -  63 
Male : female - 45:18 
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Live: cadaver - 52:11 
Pre transplant Hepatitis C positive - 20. 
Mean onset  of HCV infection  - 14+2.6 months after transplantation.  
Prevalence including prêtransplant  positivity  - 17.6%  
                     excluding  pretransplant positivity - 12.07% 
.H/o blood transfusion at the day of transplant - 8 
Associated with other  infection: 
              Hepatitis B - 7 
               Fungal infection - 16 
               TB - 6  
              CMV - 8 
             Herpes zoster - 3 
Risk factors : 
Risk factors HCV+ve HCV ve p value 
Antirejection therapy 15 85 0.443 
CNI toxicity 14 110 0.125 
 
Both ART and CNI toxicity are not coming as a statistically significant risk factors. 
Presentation: 
liver enzyme elevation - 20 
Incidental - 28 
Clinical jaundice - 15 
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Liver biopsy was done in 4 patients. One patient had fibrosing cholestatic hepatitis 
but not treated with interferon. Patient died before treatment. Other 3 had chronic active 
hepatitis. 
Outcome: 
Outcome NODAT GDF Death 
Hep C +ve 35 19 5 
Hep C  -ve 45 113 91 
p value <0.009 0.2506 <0.001 
 
55.5% of patients developing NODAT in HCV+ ve patients. (p value <0.009) 
USG  shows cirrhosis of liver  - 4 patients  
HEPATITIS B INFECTION: 
Total no. of patients -  16 
Male: female - 14:2 
Live:cadaver - 14:2 
Prevalence without previous infection- 3.9% 
                    With previous infection  - 4.4% 
Pre transplant hepatitis B –2 Patients. 
Mean duration of detection of hepatitis B - 13+2 months 
 Phase 1 (<1 month) - nil 
 Phase 2 (1-6 months)-1 
 Phase 3 (>6 month)-13 
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Risk factors: 
Risk factors With Hep B Without Hep B p value 
Anti rejection 
therapy 
5 105 >1.0 
CNI toxicity 3 121 0.1919 
GDF 5 117 >1.0 
 
Most of risk factors described in viral infection are anti rejection therapy and CNI 
toxicity  and GDF. But no factors are came as statistically significant in my study for 
hepatitis B infection. 
H/o blood transfusion - 4 patients out of 14 patients after transplant. 
Associated other infection: 
Hepatitis  C - 7 
Herpes zoster -  2 
Herpes labialis - 3 
Outcome: 
Outcome NODAT Death 
Hep B +ve 6 3 
Hep B –ve 74 93 
p value  0.214 0.572 
 
NODAT is present in 37.5% of patients. Since all 6 are associated with hepatitis C,  it 
is not applicable only to hepatitis B.  
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Presentation  
 Liver enzyme elevation - 5 
 Incidental - 7 
 Clinical jaundice - 5 
Only one case of TMA is documented and one case of cresentic glomerulonephritis is 
documented. 
Liver biopsy was done in 2 patients. 2 patients had chronic active hepatitis. 
Treatment  was started on 5 patients. 4 patients started on lamivudine  naïvely and 1 
patient started on entecavir naïvely. Out of lamivudine started patients, out of 4, three 
patients developed resistance to lamivudine and started on entecavir. 
In 2 patients USG shows cirrhosis of liver. Both 2 are Hep C and Hep B positive. 
HERPES ZOSTER INFECTION: 
Total no. of patients - 29 
Male: female  - 24:5 
Live:cadaver - 23:6 
Mean time  of onset- 9 months after transplant. 
Prevalence - 8.1% 
 Phase 1 (<1month ) - 3 
 Phase 2 (1-6month) - 11 
 Phase3 (>6month) - 15 
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Complication: 
Encephalitis - 1 
Recurrence - 2 
Severe Post herpetic neuralgia - 2 
Associated other infection: 
CMV - 2   
BK virus - 1 
HCV - 2     
Hepatitis B - 1 
Risk factors: 
Risk factors With herpes 
zoster 
Without 
herpes zoster p value 
Anti rejection therapy 13 97 0.0971 
CMV 2 60 <0.01 
CNI toxicity 8 116 0.425 
NODAT 9 71 0.356 
 
Eventhough  antirejection therapy  and NODAT and CNI toxicity described as risk 
factor, it is not statistically significant but associated CMV infection is considered as a strong 
risk factor for developing herpes zoster infection. 
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Out of 29 patients , 16 patients have multidermatomal involvement. 
Risk factors Multidermatomal Single Dermatomal p value 
Anti rejection therapy 11 2 <0.007 
NODAT 5 4 1.0 
CNI toxicity 6 2 0.237 
CMV 2 0 0.487 
 
For mutidermatomal herpes zoster involvement antirejection therapy is the strong risk 
factor (p value<0.007) 
Outcome: 
Outcome GDF Death 
With herpes zoster 8 3 
Without herpes zoster 114 93 
p value 0.541 <0.04 
 
Graft dysfunction is higher in  patients developing herpes zoster , it is not statistically 
significant. But death occurs in 3 patients. Eventhough it is statistically significant, that 
patients had also CMV infection and fungal infections. 
CHICKEN POX INFECTION: 
 Total no. of patients -  11 
 Male : female - 9:2 
 Live : cadaver - 7:4 
 Mean time of onset  -  6month + 2month 
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Occurrence : 
 Phase 1 - <1month - 2 
 Phase 2 - (1-6month) - 4 
 Phase 3 - (>6month) - 5 
Types of presentation: 
 Diffuse disease - 4 
 Localised disease - 6 
 Hemorrhagic disease - 1 
Complication : 
 Encephalitis - 1  
 pneumonia - 1 
 pancreatitis - 1 
Comorbidities: 
 HCV - 2 
 CMV - 1 
 Herpes zoster - 1 
Risk factors: 
Risk factors Chicken pox No chickenpox p value 
NODAT 4 76 0.275 
Anti rejection therapy 3 117 0.756 
 
36% of patients have NODAT and 27% of patients  had anti rejection therapy but it is 
not statistically significant. 
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Outcome: 
Outcome GDF Death 
Chicken pox +ve 2 2 
Chicken pox-ve 120 94 
p value 0.106 0.733 
 
Death occurred in 18.18% of patients. Persistent graft dysfunction occurred in 
18.18% of patients. 
HERPES SIMPLEX INFECTION: 
 Total no. of patients - 23 
 Male : female - 21:2 
 Live : cadaver - 20:3 
 Mean Time of onset - 7month + 3 months after transplantation 
 Prevalence - 6% 
Presentation : 
 Oral/palatalulcer - 5 
 Herpes simplex labialis - 14 
 HSV pneumonia - 1 
 Esophageal ulcer - 1 
 Scrotal ulcer - 1 
 Preputial ulcer - 1 
 Encephalitis - 1 
Associated with other infections: 
 CMV - 3 
 HCV - 2 
 Herpes zoster - 4 
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Risk factors:  
Risk factors Herpes 
simplex 
Without 
herpessimplex p value 
NODAT 5 75 1.0 
Anti rejection therapy 6 94 1.0 
CNI toxicity 12 112 0.118 
 
NODAT is present in 5 patients only. 
Outcome: 
Outcome GDF Death 
Herpes simplex +ve 6 2 
Herpes simplex –ve 116 94 
p value 0.498 <0.050 
 
2 Patients died.  One patient has encephalitis and one patient had pneumonia. 
HHV6 VIRUS INFECTION: 
 Only one patient is considered as HHV6 infection 
 Presentation - exanthematous fever 
 Risk  factor: CMV+ve 
EBSTEIN BARR VIRUS: 
 Total no. of patients - 2 
 Both patient had graft dysfunction 
One patient had a history of ART and treated CMV with renal biopsy  shows plenty 
of interstitial lymphocyte infiltration. One patient is present as pulmonary nodule and hilar 
lymphadnopathy  
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PARVO VIRUS: 
 Total no.of patient-3 
 Male:female=2:1 
 Live:cadaver=2:1 
 Prevalence-0.8% 
Associated with other viral infection:  
 HCV-1 
Other risk factor: 
 Graft dysfunction-1 
 CNI toxicity-1 
 2 patients present  as pure red cell aplasia 
 One patients had collapsing glomerulopathy. 
ADENOVIRUS: 
 Total no.of patients:3 
 Male:female=2:1 
 Live:cadaver=2:1 
 Prevalence-0.8% 
 Mean time of onset –3 month+1 month after transplantation. 
Presentation:  
 2 patients have hematuria 
 1 patient had interstitial hemorrhage in biopsy 
Associated with other infection: 
 Herpes zoster-1 
 HCV-1 
Risk factors: 
 NODAT-1 
 ART-1 
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Outcome: 
 GDF-2 
 Graft loss-1 
HUMAN PAPILLOMA VIRUS: 
 Total No. of patients - 7 
 M : F -  6:1 
 Prevalence - 1.9% 
 Mean time at the onset - 18 month + 6 month after transplantation. 
 Presentation as a cutaneous warts - 7 
Risk factors: 
 ART-1   
 NODAT-1 
Associated with infection: 
 HCV - 1 
 herpes zoster - 1 
HIV INFECTION:  
 Only one patient had ELISA positive after 1½ year. 
 H/o blood transfusion after transplant.  
 No h/o other hepatitis b or c infection 
 No h/o sexual misconduct or IV drug abuse. 
 Presently no opportunistic infection present. 
 CD4 count - 300cells/cu.mm 
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DISCUSSION 
In our study 356 patients were taken. Out Of which 152 persons were affected by 
viral infection.   42.6 % affected by viral infection.  
Total Number of viral infective episodes were 224. Total infective episodes 741.  
Bacterial infection excluding mycobacterium TB accounts for 45%.  Viral infections 
accounts for 30.5% 
Fungal infection accounts for 9.5% and mycobacterium TB  accounts for 10.8% and 
parasitic infection accounts for 5.2%.  Dharnidharka et al 49Bacterial infection are twice as 
frequent as viral infections and among bacterial infections  vascular access and urinary tract 
infections are the commonest and among viral infection cytomegalovirus infection is the 
commonest. 
We divided into 3 phases . I phase- less than one month after transplantation. II Phase 
1-6 months. III  phase more than 6 months. Out of 3 phases Phase III has more viral infective 
episodes (53.1%) and followed by  Phase II (33%) and lastly Phase I (4%).In Phase II CMV 
infection is the commonest. Stratta et al50 opine that 1st month bacterial infection is the 
commonest  and 2nd - 4th  month CMV predominates the bacterial  and mean timing of 
bacterial infection  is 60 days and mean onset of CMV is  70 days and non CMV viral  is 145  
days and fungal is 163 days 
Most of the risk factors analysed for developing viral infection are state of 
immunosuppression and antirejection therapy and NODAT and CNI toxicity and graft 
dysfunction . In our study anti rejection therapy (p-0.004) and NODAT(P-0.001) are the  
significant risk factors for developing viral infection. 
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In the outcome analysis, 53.5% of viral infected persons have  persistent graft 
dysfunction. The Graft loss occur in 9% of persons in our viral infected study population  and 
death occurred in 11.8% of patients. Viral infection is one of the major determining  factor 
for graft and patient survival.  
CMV infection: 
Prevalence of CMV disease in our study is 17.4%. The risk of CMV infection 
depends on the serology and immunosuppression and antiviral prophylaxis. In our hospital 
we are not checking for the serology status of recipient and donor and also not giving 
prophylactic antiviral therapy for all patients. Most of the studies are representing the 
incidence of CMV infection between 8 to 32%. Kotton Cn etal with conventional 
immunosuppressive regimens 10 to 15% of get active CMV  infection33. Kanter et al 32 
patients (15.7%) had active CMV infection51. In our study mean time of onset of CMV 
infection is 4+1 month. Green et al  in the absence of prophylaxis the  mean time of detection 
of CMV is between 1-3 months52. In the presence of  prophylaxis seen after 90 days.  
In our study around 65% of disease occur in less than 6 month. Late onset of CMV 
infection occur in 34% of our study population. Helantra et al53 late onset of CMV infection 
47/127( 37% ) of patients. 
Most common presentation of CMV is cytomgalovirus syndrome . In our study 37 
patients (59.6%) had CMV viral syndrome. Arthurss et al 54said about CMV syndrome 
accounts for 60% of all cases of CMV disease. Colitis present in  19.3% of patients. Halentra 
etal53 in his study colitis present in 24/127 (18.3%) of patients. Retinitis is present in late 
onset of CMV disease55. In our study  2 patients present in late after 6 months only (3.2%) 
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.Arthurs et al 54 in his study 2% of patients with retinitis. Leucopenia present in 72.5% of 
patients . it is the significant risk factor and also severity of CMV disease in our study. 
Recurrent CMV occur in 3 patients in our study (5%).   Halenthra et al53 in his study 
19% had recurrent CMV. In  our study late onset CMV disease  2 patients develop resistance 
to ganciclovir.  V Jha et al100 15% of late onset disease was due to drug resistant strains. In 
our study 9.2% of late onset disease due to drug resistant strains. This is less comparatively 
because of not using prophylactic therapy. 
Risk factor analysis, eventhough CNI level and toxicity and NODAT correlating with 
high incidence of infection, our study anti rejection therapy  and rejection is the statistically 
significant risk factor for CMV infection. Boratynska M 56et al told that acute rejection is a 
major risk factor  for CMV disease and disease occur in three  quarters of patients during the 
month following an episode of rejection . In our study 46% had h/o rejection and Anti 
rejection therapy. 
Invasive bacterial and fungal infection are highly associated with CMV diseases 
because proinflammatory condition associated with infection reactivate the virus. Conversely 
CMV disease increase the risk of opportunistic bacterial and fungal and other viral  
infection57.  In our study also, CMV is the statistically significant risk factor for bacterial and 
fungal and other viral infection but not with mycobacterium tuberculosis. 
CMV infection is  the risk factor for graft dysfunction and graft loss. Our study CMV 
is significant predictable risk factor for graft dysfunction and death. S Sagedel 57 etal told that 
CMV disease  is the independent risk factor for overall mortality beyond 100 days of post 
transplantation and reduced graft survival. 
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Comparing the early and late onset of CMV infection , late onset of CMV infection is 
more correlating with graft dysfunction and mortality. Limaye AP etal58  said that late onset 
disease is a strong predictor of mortality and graftloss. Our death rate was 22.5%. In Arthurs 
Sk et al54 study 20% of patients died  
BK virus : 
In our study prevalence-0.8%. Most of the studies59 quoting 1%-10% of renal 
transplant recipients acquired BK virus infection  In our study it is less because due to 
logistic reasons we are not done DNA PCR and only doing urine decoy cells if it is positive 
then only we are doing, so it may lesser than the actual value. Mean time of onset in our 
study – 8 month . Most of the studies60,61 show occurs within one year and also 1-3 months 
and beyond 1 year also. 
All the 3 patients now  with graft dysfunction. Ramos et al15 in n BK virus infection,  
progressive renal failure occurs in 60% of patients.  One patient presenting as a ureteric 
stenosis. Gupta etal62 described BK virus can cause ureteric stricture and hydronephrosis. 
Two patients had intersitital nephritis. Howell Dn etal63 describes the interstitial 
infiltrates and tubular cytopathic changes in BKVN.  In Biopsy one patient had intranuclear 
viral inclusion bodies in epithelial cells. Nickeleit etal64 told that intranuclear viral inclusion 
bodies in epithelial cells along the entire nephron and the transitional cell layer are hall marks 
of BK virus nephropathy. Affected tubular cells are enlarged and often necrotic.  
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Hepatitis C infection : 
Prevalence of Hepatitis C in post renal transplant recipients in our study 17.06% 
including pre transplant Hepatitis C positive if we excluded the pre transplant positive 
recipients then  it is 12.5%. Most of the studies 65-67said the prevalence varies from 6% -46%. 
In our study cirrhosis occurs in 6.3% of patients. Many studies report68,69 that cirrhosis is 5 to 
21% during 3 to 7 year follow up. 
NODAT is  seen in our study 55.5%. Cosio FG et al70 his study 24% of patients 
develop NODAT. HCV is the strong statistically significant risk factor for NODAT in our 
study. A recent meta analysis71 of 10 studies in 2502 renal transplant recipients showed a 
strong link between anti HCV seropositivity and post transplantation diabetes . 
Acute rejection episode in our study was 23.8%. Jose Maria Morales72 et al in his 
study acute rejection rate was 32.5% and biopsy proven CAN was 34.4%. In our study 
biopsy proven IFTA 20.6%.  
Only one patient had fibrosing cholestatic hepatitis and patient was died before 
starting of IFN therapy. IFN treatment of renal transplant recipients with HCV infection has 
been suggested  to be considered only when the risk of not implementing treatment justifies 
the possible loss of the allograft, for example in patients with fibrosing cholestatic hepatitis 
or lifethreatening vasculitis. (KDIGO guidelines). 
Death is high in those who have HCV infection. In our study it is statistically 
significant.  Periera  and coworkers compared the prevalence of  post transplantation liver 
disease in HCV positive recipients. Those who have positive before transplantation, the 
 53 
relative risk of liver disease was 5, graft loss was 1.3 and death was 3.3. There was increase 
in death resulting from sepsis with a relative risk of 9.9.25  
Hepatitis B virus: 
The prevalence of Hepatitis B infection in renal transplant recipients -3.9%. Santos  et 
al his previous studies showed 6.2% and recent studies shows 2.6%73.  Tsai etal74  in his 
study prevalance was 9.2% .Concomitant hepatitis B and hepatitis C was 1%. Rejection rate -
31.2%.   Santos et al73  his studies shows 0.7%. Santos et al his study rejection rate 46.4% 
Mean duration after transplantation hepatitis B activation in our study is 13+2 
months. Degos et al77 mean duration of hepatitis B activation is 3-12 months. 
Lamivudine resistance was 3/5 (60%) in our study. Thabut et al75 shows lamivudine 
resistance is 57%. Kamar et al in his study lamivudine resistance in renal transplant 
recipients is 67%74. So In KTR recipients first itself start on entecavir to reduce the genetic 
barrier   for resistance and nephrotoxicity78. In our study enzyme elevation with jaundice in 
31.5% of patients. Su Kil Park et al76 in his study 7 out of 14 (50%) of patients shows either 
clinical  and biochemical manifestation of hepatic dysfunction. Mathurin et al79 showed that 
in a cohort of 128 renal transplant recipients infected with HBV the 10 year survival was 
55% compared with 80% in non hepatitis B infected renal transplant recipients.   In our study 
Death rate was 18%. 
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Herpes Zoster infection: 
Prevalence of herpes zoster infection in our study - 8.7%. Other studies recorded  a 
prevalence of 3-10%34,80. In our cohort males are - 82%. Normally female gender is the risk 
factor for developing herpes zoster in liver transplant recipients not confirmed in renal 
transplant recipients. Median time of onset of herpes zoster is 9 month in our study. Previous 
studies between 3 and 92 months after transplantation.81 
Disseminated with visceral involvement in only one case (3.4%).  T.Arnes et al84  
8.1% with visceral involvement with encephalitis and pneumonia..Mustapic et al82 in his 
study also 2/37 had post herpetic neuralgia. In our study, 2/29 patients had post herpetic 
neuralgia. Recurrence occurs  in 6.8%. Webster et al 83 in his studies second episode of 
herpes zoster in 5-15% of transplants. 
In single dermatomal  common region involved  is throax followed by lumbosacral 
region. T Arnes et al84 in his study  throax 29.7% involved and followed by lumbosacral 
(16.7%). 
We did not get statistically significant association between anti rejection therapy and 
varicella zoster. But CMV infection is a risk factor for developing herpes zoster. But in 
multidermatomal herpes zoster antirejection therapy comes as a significant risk factor. 
Arness etal84 in his study also anti rejection therapy was not come as a significant risk factor. 
In our study graft dysfunction is not associated with herpes zoster but herpes zoster is the 
significant risk factor associated with patient survival. 
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Chicken pox infection: 
Prevalence of chicken pox in our study - 3%. Most of the studies around 1-2%85 Time 
of occurrence - 50% occurrence in < 6 months. One study 40% of case occur less than 6 
months.86 
Localized lesions in 54.5% patients. But Anupama kaul stated  that 65.2%  had 
localized disease.85  In our study either Anti rejection therapy or NODAT   are not come   as a 
risk factor for chicken pox. 
Death rate was 18.8%. Anupama kaul etal85 his study 13.3% due to associated CNS 
infection and secondary bacterial infection. In our study also these 2 patients had encephalitis 
and superadded bacterial infection.  Persistent graft dysfunction occurs in  18.18% of 
patients.  Anupamaetal85  in his study 29.8% had graft dysfunction after chickenpox . 
Herpes simplex infection: 
Prevealence of  herpes simplex infection in our study 6%. Smith  et al his 
prevalence20%87 
Time of their presentation- mostly within 3 months. in our study 6 month + 2 months. 
Only one case of encephalitis  reported in our study. HSV is the most common cause of 
encephalitis in transplant recipients. One case of esophageal ulcer documented in our study. 
HSV esophagitis can cause dysphagia and may occur if the mucosa of an infected individual 
has been traumatized by nasogastric tube or endotracheal intubation.87 Death occurred in 2 
patients in our study. One patient had encephalitis and one patient had severe pneumonia.            
A small subset of patients (3.5%) has acyclovir resistant herpes simplex infection.36 
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HHV6 Infection: 
 Only one case reported. This patient had CMV  infection also. This patient presented  
with rash. 
HHV 6 virus causes exanthema subitum and HHV7  causes similar type of rash, 
leucopenia with lymphocytosis and spleenomegaly. Reactivation occurs in 60% of patients. It 
is possible CMV disease like symptoms with rash but negative for CMV may be attributable 
to HHV 6 infection87. Studies shows that CMV infection  either precipitate or activated by 
HHV6 infection88. 
Ebstein barr virus infection: 
In our study 2 patients had post transplant lymphoproliferative disorder due to ebstein 
barr virus infection. One patient presented as a graft dysfunction and  lymphadnopathy and 
hepatomegaly Graft biopsy shows sheets of lymphocytes infiltrated into the interstitium. 
Another  patient presented in one and half year after transplantation with chest discomfort 
and CT chest shows mutiple pulmonary nodule and hilar lymphadenopathy and cervical 
lymphadenopathy and graft dysfunction we didn’t do graft biopsy for that patient. But  we 
did lymph node biopsy and bone marrow aspiration  and  PET scan was done and it is proved 
to be Post transplant lymphoproliferative disorder. But treatment not yet started and  lost 
follow up. Prevalence  in our study was 0.5%.  In kidney transplant recipients 1-2%89.  PTLD 
is occur within one year of transplantation and is more common iin children91. 
Immunosuppresive drugs may produce activation  and prolieration of EBV virus among B 
lymphocytes increase the chance of developing PTLD90. Recently PTLD incidence less 
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because use of lower immunosuppressive drugs and use of induction agents IL2 receptor 
antagonists and use of prophylactic vanganciclovir prophylaxis3.  
Parvo virus infection: 
In our study 3 patients have parvo virus infection. Prevalence was 0.8%. On the basis 
of several studies the prevalence between 1-12%92 . Two patients were  presenting as a pure 
red cell aplasia one in 4th month and another patient in 9th  month  after  transplant. Normally 
Onset of B 19 associated anemia has reported from 2 weeks to 63 months after 
transplantation93.  Our patient does not have any typical of arthritis or rash and bone marrow 
aspiration shows pure red cell aplasia. Quantitative  DNA PCR was positive. One patient was 
presented with graft dysfunction and protienuria and biopsy shows collapsing 
glomerulopathy and qualitative PCR for Parvo was positive. 
Moudgil et al94 reported the link between collapsing glomerulopathy and parvovirus. 
Adeno virus infection: 
Prevalence of adenovirus infection - 0.8% in our study. Mean time of  onset occurs 
within 6 months of transplantation95.  Our study also correlates this statement. Most 
frequently reported clinical syndrome has been hemorrhagic cystitis due to adenovirus type 
11.96 Our patients are also present with hematuria. One patient had graft loss and other two 
patients had persistent and progressive graft dysfunction. One patient was  suspected to be 
acute cellular rejection and treated with antirejection therapy but serum creatinine not 
touched the baseline. Adenovirus can also present as a pyelonephritis.97 
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Human Papilloma virus infection: 
Total number of patients -7 all are present with cutaneous warts. 
Prevalence-1.95%.  Cutaneous warts and precancerous lesions normally 15% at the 
time of transplantation and increased to 80% after 20  years, Sun exposed areas the face, 
neck, arm involved more commonly98 Rudlinger et al.  in his study  (48%) were found to 
have warts,  (11%) keratosis and  (5%) to have, or recently to have had cancers. The longer 
the time of immunosuppression, the greater the prevalence of warts; Of those patients who 
had had their transplant for at least 5 years, 87% had warts.   (10%) of 50 women had genital 
warts, four of them had internal lesions (vaginal, cervical or anal) and one developed a 
carcinoma of the vulva. 
HIV Virus : 
Only one patient had HIV ELISA is positive. He didn’t have any history of sexual 
promiscuity or IV drug abuse. His CD4 count  300 cells/cu mm. Patient  had  HIV ELISA 
negative before transplant. He had no episode of rejection. Roland etal 99 survival rate for the 
patient (92%) and graft (85%) in 10  months were comparable to HIV negative patient rates. 
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Conclusion: 
1. Bacterial, viral, fungal and  parasitic infection contributes to 45%, 30.5%, 9.5%, 
5.3%  respectively to the  total infective episodes. 
2. Most of the viral episodes occurred after 6 months post transplant. 
3. Commonest viral infection is the CMV and its prevalence 17.4% and mean time of 
onset is between 1-6 months after transplantation. 
4. On Univariate analysis, antirejection therapy and NODAT  had  statistical 
significant risk factor for developing viral infection (P<0.05) 
5. In patients affected with  viral infection on univariate analysis, there is a statistical 
significance for graft dysfunction, graft loss and death (p<0.05) 
6. CMV infection has a statistical significant risk factor for bacterial, fungal and other 
viral infections. (p<0.05) 
7. Hepatitis C infection is the second most commonest virus found in our study, mean 
onset of infection is seen 6 months after transplant. Nearly 50% HCV infected 
patients developed NODAT. 
8.  Lamivudine resistance is more common in post transplant situation because 
prolonged treatment is necessary. 
9. All the three patients with BK virus infection had  persistent graft dysfunction. 
10. Multi dermatomal involvement is commonly seen in our patients with herpes 
zoster(56%).  
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KEY TO MASTER CHART 
DOT     - date of transplant 
F.U      - follow up duration 
Cr.f.     - creatinine at follow up 
Gd        - graft dysfunction 
G.s       - graft survival 
G.L      - graft loss     1 -  present    2 - graft lost 
P.S     - patient survival         2 -  died 
DA     - donor age 
Chi       - chicken pox 
H.Z   - herpes zoster            
Hes     - herpes simplex                                  
Ade    - adeno  
H6   - human herpes virus 6  
Pro  - parvo 
EBV   -  ebstein barr virus 
HPV   - human papilloma virus 
HCV    - hepatitis B virus 
TB  -  tuberculosis 
Fun  - fungal 
I.s  - immunosuppressants 
Cyclo/Aza  - 1 
Cyclo/MMF- 2 
Tacro/MMF- 3 
Tacro/aza - 4 
1 - present 
2 - absent 
PROFORMA 
POST TRANSPLANT VIRAL INFECTION 
 
Name                                         Age                Sex              Date of transplant 
NKD                                            
Donor                                       Age                 Sex                             
Pre transplant cmv status of donor                        Recipient 
Pretransplant Hepatitis B                     prettransplant hepC                       Pretransplant any other 
Hepatitis B vaccination                                                                   Varicella vaccination 
Pre transplant hepB treatment and viral load 
Warm ischemic time                                                           Cold ischemic time 
Immunosuppression                                                                Induction agent 
Rejection                                                                                 CNI toxicity 
Biopsy                              
HB                              Total wbc                    DC                   Platelets              Periph smear 
Retic count                 LDH                    coombs 
Urine R/E   urine c/s                      blood c/s 
LFT        T.Bil          dire           indirect               OT            PT            ALP       T.p      alb      glob 
Blood  sugar             urea                         creatinine                      electrol 
X ray chest 
Viral markers HBs ag             HIV           HCV               anti HAV                 anti HEV 
CT Chest                                                                                     PET 
 
Usg abdomen                                                                            renal Doppler 
 
CSF exam   microbial                      Prot                                  Serology 
Pleural fluid                                                                       Ascitic Fluid 
 Upper gi endos                                                       Colonos 
BAL                                         Cytology                Culture 
Bone marrow aspiration                      Bonemarrow biopsy 
 
Liver biopsy 
 
Skin biosy 
Tzanck smear: 
Association of other bacterial / fungal infections -  time                Culture 
CMVinfection                   Months after transplant 
Cmv pp65                                         CMV PCR                               Repeat 
Type  of presentation-viral syndrome/retinitis/colitis/pneumonits /hepatitis /ulcer 
Treatment status               Responsiveness 
BK virus:                         Months after transplant. 
Urine for decoy cells                                                                 Quan PCR         
Hepatitis C virus                    Month aft trx 
Quant pcr      
Treatment                                         Responsiveness 
Hepatitis b virus                    Month after tx 
Quanti PCR                   
Treatment                                           Responsiveness 
Herpes zoster                             Month after tx                        Recurrence 
Multidermato/single dermatome                       
Complication:encephalitis/post herpetic neuralgia/cut scarring 
Treatment                                        Responsiveness  
Chicken pox:                   Month after TX                           
Complication 
Treatment 
Herpes simplex:                     Month after tx 
Type of presentation       
Treatment                                           Responsiveness 
EBV:                                  Month after TX 
Type of presentation: 
Treatment                                          Responsiveness 
Other herpes viruses: 
Type of presentation                          Treatment   
Parvo virus:                      Month after tx 
Qunat PCR                               
Adenovirus:                   Month after Tx 
Type of presentation                         Treatment 
Human papilloma  virus :      Month after Tx 
Type of presentation                  Treatment  
Other viruses: 
 
 
 
 
               
 BoneMarrow Aspiration--Megakaryocytes  adequate. myelopoiesis normal. 
Red cell precursors decreased   - pure red cell aplasia (parvo virus induced) 
 
 
 
Allograft biopsy shows viral inclusion 
 
TOTAL INFECTIVE EPISODES 
 
 
 
TIME OF  OCCURRENCE OF VIRAL INFECTIVE EPISODES 
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TIME OF  OCCURRENCE OF OTHER VIRUSES 
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OTHER VIRUSES 
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IMPACT OF HCV ON PATIENT SURVIVAL 
 
 
  
  
 
  
